Efgartigimod IV: Clinical Trials

12 trials of Efgartigimod IV, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 completed, 4 recruiting, 2 active not recruiting, 1 terminated. 6 Phase 3, 5 Phase 2, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	6	Active not recruiting 2, Completed 2, Recruiting 2
Phase 2	5	Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1
Phase 1	2	Completed 2

Follow Efgartigimod IV: new trials by email Literature Review of Efgartigimod IV trials Research Report on Efgartigimod IV

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis Efgartigimod IV, Empasiprubart IV, Placebo IV - Myasthenia Gravis, MG		Recruiting	argenx	70	2025-12-19	2026-10-26
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod Efgartigimod IV, Empasiprubart IV - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis	Phase 2	Recruiting	argenx	70	2025-12-19	2026-09-24
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia	Phase 2 / Phase 3	Recruiting	argenx	24	2025-10-20	2026-10-16
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Efgartigimod IV, Placebo IV - Primary Immune Thrombocytopenia (ITP)	Phase 3	Recruiting	argenx	69	2024-10-18	2026-05-01
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Efgartigimod IV, Placebo IV - Generalized Myasthenia Gravis, gMG	Phase 3	Active not recruiting	argenx	119	2024-04-16	2026-08-10
A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod Efgartigimod IV - Renal Impairment	Phase 1	Completed	argenx	33	2023-07-17	2024-06-26
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) efgartigimod IV, Placebo - Lupus Nephritis	Phase 2	Completed	argenx	73	2023-02-21	2025-12-18
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) efgartigimod IV, placebo - Membranous Nephropathy	Phase 2	Terminated	argenx	8	2023-02-20	2024-11-22
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis Efgartigimod IV - Generalized Myasthenia Gravis, MG - Myasthenia Gravis	Phase 3	Completed	argenx	69	2021-12-16	2026-05-27
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Efgartigimod IV - Generalized Myasthenia Gravis	Phase 2 / Phase 3	Active not recruiting	argenx	15	2021-10-26	2026-10-29
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis efgartigimod PH20 SC, efgartigimod IV - Generalized Myasthenia Gravis	Phase 3	Completed	argenx	110	2021-02-05	2023-02-28
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers efgartigimod IV, efgartigimod PH20 SC - Healthy Volunteers	Phase 1	Completed	argenx	54	2020-08-18	2021-04-05

Conditions studied

Sponsors

Countries

NIH funding